<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Incontinentia pigmenti
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Incontinentia pigmenti
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Incontinentia pigmenti
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Moise L Levy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 17, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H613025497">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incontinentia pigmenti (IP; Bloch-Sulzberger syndrome, MIM #308300) is an X-linked dominant genodermatosis that is usually lethal in males before birth [
         <a href="#rid1">
          1-4
         </a>
         ]. IP is caused by loss-of-function mutations in the
         <em>
          IKBKG
         </em>
         (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma) gene, formerly known as
         <em>
          NEMO
         </em>
         (nuclear factor-kappa-B essential modulator), encoding a regulatory protein named IKK (NEMO) that activates genes involved in cell survival, inflammation, and immunity [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         The disorder is seen almost uniformly in females, although it may occasionally occur in males with somatic mosaicism or XXY karyotype (Klinefelter syndrome) [
         <a href="#rid1">
          1
         </a>
         ]. In females, IP typically presents with a staged, linear, cutaneous eruption and often with anomalies of the teeth, hair, nails, and retina [
         <a href="#rid4">
          4
         </a>
         ]. Approximately one-third of patients have ocular and neurologic abnormalities. Because of the involvement of skin, hair, nails, and teeth, IP can be considered a form of ectodermal dysplasia [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         This topic will discuss the pathogenesis, clinical presentation, and diagnosis of IP. The ectodermal dysplasias are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">
          "Ectodermal dysplasias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1471478818">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         IP occurs in approximately 1:40,000 to 1:50,000 births [
         <a href="#rid1">
          1,3
         </a>
         ]. Virtually all cases are seen in females because affected males usually do not survive until birth. Males born with the condition have either somatic mosaicism or an XXY karyotype (Klinefelter syndrome) [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13921.html" rel="external">
          "Clinical features, diagnosis, and management of Klinefelter syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3066664093">
         <span class="h1">
          MOLECULAR PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the majority of cases, IP is due to mutations in the
         <em>
          IKBKG
         </em>
         (inhibitor of kappa light polypeptide gene enhancer in B cells) gene, also known as
         <em>
          NEMO
         </em>
         (nuclear factor-kappa-B essential modulator), located on chromosome Xq28 [
         <a href="#rid6">
          6,8
         </a>
         ]. These mutations occur "de novo" in approximately 65 percent of the IP cases.
        </p>
        <p>
         <em>
          IKBKG
         </em>
         encodes the I-kappa-B kinase (IKK)-gamma protein (also called NEMO), a regulatory subunit of the inhibitor of the IKK complex, which activates nuclear factor-kappa-B, leading to the activation of genes involved in cell survival, inflammation, and immunity. (See
         <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">
          "Combined immunodeficiencies: Specific defects", section on 'IKBKB deficiency'
         </a>
         .)
        </p>
        <p>
         Approximately 90 percent of the
         <em>
          IKBKG
         </em>
         mutations in IP are deletions of exons 4 to 10, resulting in complete loss of IKK-gamma function [
         <a href="#rid9">
          9-11
         </a>
         ]. Microdeletions, missense, frameshift, nonsense, and splice-site mutations leading to complete or partial loss of IKK-gamma activity account for the remaining cases [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Null mutations are lethal in utero in males, whereas females survive because of X chromosome mosaicism (lyonization). Milder (hypomorphic)
         <em>
          IKBKG
         </em>
         mutations that impair, but do not abolish, nuclear factor-kappa-B signaling have been found in males with a rare form of X-linked anhidrotic ectodermal dysplasia associated with immunodeficiency (MIM #300291) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">
          "Ectodermal dysplasias", section on 'Ectodermal dysplasia and immunodeficiency'
         </a>
         .)
        </p>
        <p>
         Cells lacking IKK-gamma are targets for tumor necrosis factor-induced apoptosis [
         <a href="#rid13">
          13,14
         </a>
         ]. Multiple reports describe reactivation of IP skin lesions from stressors such as vaccines, fevers, and laser treatment [
         <a href="#rid15">
          15,16
         </a>
         ]. It is thought that mutated cells may be vulnerable to unregulated apoptosis in these circumstances. Moreover, IKK-gamma deficiency affects several signaling pathways associated with bone and vascular function and anatomy, as well as immune function [
         <a href="#rid1">
          1,11
         </a>
         ].
        </p>
        <p>
         It has been suggested that both ocular and neurologic abnormalities in IP may result from a developmental cerebral small-vessel disease induced by the inactivation of
         <em>
          IKBKG
         </em>
         and, possibly, by the disruption of the transforming growth factor (TGF)-beta-activated kinase (TAK1) upstream of
         <em>
          IKBKG
         </em>
         [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1839186005">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1560587832">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The heterogeneity in the clinical presentation of IP and the apparent lack of genotype-phenotype correlation may be due to the random inactivation of one of the two female X chromosomes (lyonization), which occurs early during embryogenesis and varies depending on tissues. The X-inactivation is extremely skewed in cells expressing the mutated X chromosome, thus favoring the elimination of the mutated
         <em>
          IKBKG
         </em>
         allele in nearly 90 percent of cases [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Due to the X-linked dominant nature of IP, virtually all patients are female. Although the condition is usually lethal for males prenatally, a few cases have been reported in males [
         <a href="#rid7">
          7,20-22
         </a>
         ]. Survival in males is due to somatic mosaicism or chromosomal aneuploidy (47,XXY; Klinefelter syndrome). (See
         <a class="medical medical_review" href="/z/d/html/13921.html" rel="external">
          "Clinical features, diagnosis, and management of Klinefelter syndrome"
         </a>
         .)
        </p>
        <p>
         The clinical features of IP are variable, and there is no clear genotype-phenotype correlation. However, in nearly all patients, the characteristic cutaneous lesions are the first manifestation of IP  (
         <a class="graphic graphic_table graphicRef109835" href="/z/d/graphic/109835.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H149959013">
         <span class="h2">
          Cutaneous findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the classic presentation, the cutaneous lesions of IP present in a female infant at birth or in the first few months of life and evolve through four characteristic, overlapping stages  (
         <a class="graphic graphic_table graphicRef109835" href="/z/d/graphic/109835.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 1 (vesicular)
         </strong>
         – Patterned, tense vesicles and/or pustules, usually overlying an erythematous base, are in most cases noted at birth, or shortly after, on the trunk and extremities  (
         <a class="graphic graphic_picture graphicRef111088 graphicRef58769" href="/z/d/graphic/111088.html" rel="external">
          picture 1A-B
         </a>
         ). These lesions seem to develop along the Blaschko lines  (
         <a class="graphic graphic_figure graphicRef57219" href="/z/d/graphic/57219.html" rel="external">
          figure 1
         </a>
         ), which represent the embryologic pathways of migration of cutaneous and appendageal cells, and persist for months [
         <a href="#rid23">
          23
         </a>
         ]. At this stage, the affected infant will often show eosinophilia on routine complete blood counts. This finding might be due to overexpression of eotaxin, a chemotactic factor for eosinophils, which may occur in the setting of
         <em>
          IKBKG
         </em>
         mutations [
         <a href="#rid1">
          1
         </a>
         ]. These may persist into adulthood [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 2 (verrucous)
         </strong>
         – Following the initial skin eruption, lesions become more papular or crusted ("wart-like") and maintain their localization along the Blaschko lines  (
         <a class="graphic graphic_picture graphicRef89806 graphicRef53297" href="/z/d/graphic/89806.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a href="#rid3">
          3,25
         </a>
         ]. This stage usually lasts for a few months, but it can persist for years. It may not occur in all patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 3 (hyperpigmented)
         </strong>
         – By 6 to 12 months of age, infants show brown or gray-brown, linear and/or swirling macules  (
         <a class="graphic graphic_picture graphicRef111089 graphicRef63009 graphicRef89807" href="/z/d/graphic/111089.html" rel="external">
          picture 3A-C
         </a>
         ). Stage 3 typically lasts through early adolescence and can persist into adulthood in most patients [
         <a href="#rid24">
          24
         </a>
         ]. In some cases, they will resolve completely or will be followed by a so-called "fourth stage."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 4 (atrophic/hypopigmented)
         </strong>
         – This stage is marked by hypopigmented and slightly atrophic, linear macules/patches and is often associated with alopecia. In most patients, stage 4 does not occur.
        </p>
        <p>
        </p>
        <p>
         The clinical presentation in male patients is the same as in female patients. In series of 40 boys with IP, the typical stage 1 vesicular eruption was the most frequent presentation at birth [
         <a href="#rid26">
          26
         </a>
         ]. Stages 2 and 3 were observed in approximately two-thirds of the patients. Extracutaneous manifestations, including neurologic, ophthalmic, and dental anomalies, were present in approximately one-third of patients.
        </p>
        <p>
         The onset, duration, and degree of overlapping of these stages vary among patients; stage 1 lesions can recur during a febrile illness, laser treatment, vaccination administration, or without a specific trigger [
         <a href="#rid15">
          15,27
         </a>
         ].
        </p>
        <p>
         The mother of a child with IP may be asymptomatic or show manifestations of the disease [
         <a href="#rid24">
          24
         </a>
         ]. These include hypopigmented, atrophic streaks along the Blaschko lines; nail dystrophy; and ocular, neurologic, or dental abnormalities. The diagnosis may not be made until the birth of an affected child.
        </p>
        <p class="headingAnchor" id="H3194089108">
         <span class="h2">
          Extracutaneous findings
         </span>
        </p>
        <p class="headingAnchor" id="H2430076327">
         <span class="h3">
          Dental and oral anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed dentition, pegged or conical teeth, as well as anodontia or hypodontia resembling hypohidrotic ectodermal dysplasia are seen in most patients with IP  (
         <a class="graphic graphic_picture graphicRef126603" href="/z/d/graphic/126603.html" rel="external">
          picture 4
         </a>
         ). Other oral anomalies that can occur in patients with IP include cleft or high-arched palate and decreased salivary secretion [
         <a href="#rid10">
          10,28,29
         </a>
         ]. In a systematic review of 513 published cases of IP (54 males), the overall prevalence of dental and oral anomalies was 54 percent, with 95 percent being dental anomalies [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3844793394">
         <span class="h3">
          Anomalies of the skin appendages
         </span>
         <span class="headingEndMark">
          —
         </span>
         Scalp and body hair abnormalities are seen in approximately 25 percent of patients [
         <a href="#rid10">
          10
         </a>
         ]. These include cicatricial alopecia; sparse hair; woolly, wiry, or uncombable hair; and anomalies of the eyebrows and eyelashes  (
         <a class="graphic graphic_picture graphicRef126604" href="/z/d/graphic/126604.html" rel="external">
          picture 5
         </a>
         ).
        </p>
        <p>
         Nail dystrophy may develop in approximately 10 percent of patients, usually during adolescence or early adulthood  (
         <a class="graphic graphic_picture graphicRef126617" href="/z/d/graphic/126617.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. It usually involves most or all of the fingernails and toenails. In some patients, osteolytic lesions of the underlying bone have been noted. Painful, subungual, dyskeratotic tumors are rarely associated with IP and are usually seen in adult patients [
         <a href="#rid31">
          31-33
         </a>
         ]. These tumors are frequently misdiagnosed as squamous cell carcinomas or keratoacanthomas.
        </p>
        <p>
         Breast and nipple anomalies, such as breast hypoplasia and aplasia, nipple hypoplasia, and supernumerary nipples, have also been reported with increased frequency in adult patients with IP [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1550422447">
         <span class="h3">
          Ocular anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ocular anomalies have been reported in patients with IP with varying frequency, ranging from approximately 20 to 80 percent of patients [
         <a href="#rid10">
          10,35
         </a>
         ]. They include proliferative retinopathy, microaneurysms, peripheral avascularity, areas of nonperfusion, and macular occlusive disease [
         <a href="#rid36">
          36-38
         </a>
         ]. In a review of 831 patients with IP, 37 percent had ocular anomalies, 50 percent of which involved the retina [
         <a href="#rid10">
          10
         </a>
         ]. Microphthalmia has been reported in approximately 6 percent [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1738894269">
         <span class="h3">
          Central nervous system anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central nervous system (CNS) abnormalities occur in approximately 25 to 50 percent of patients with IP [
         <a href="#rid24">
          24,39
         </a>
         ]. Neurologic symptoms, which include lethargy, poor feeding, seizures, neurocognitive impairment, and stroke, have been described [
         <a href="#rid10">
          10,13,24,40
         </a>
         ]. CNS abnormalities are in many cases associated with ocular anomalies [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Ocular anomalies'
         </a>
         above.)
        </p>
        <p>
         CNS anomalies can be demonstrated by neuroimaging studies, including magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) [
         <a href="#rid17">
          17,41,42
         </a>
         ]. In one report of eight infants with IP, abnormal MRI findings included patchy signal changes in the cortical gray matter and subcortical and periventricular white matter on T1- and T2-weighted sequences, which match areas with restricted diffusion on DWI, suggesting local inflammation and ischemia as well as hemorrhagic lesions [
         <a href="#rid41">
          41,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3981476163">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         While reports suggesting immune defects in patients with IP do exist, this association is well known in patients with the ectodermal dysplasia/immunodeficiency phenotype, rather than in the more typical patients with IP [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110146.html" rel="external">
          "Ectodermal dysplasias", section on 'Ectodermal dysplasia and immunodeficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">
          "Combined immunodeficiencies: Specific defects", section on 'IKBKB deficiency'
         </a>
         .)
        </p>
        <p>
         Rarely, cardiovascular abnormalities and pulmonary hypertension have been reported in infants with IP [
         <a href="#rid46">
          46-49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H540012219">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A skin biopsy may be especially helpful in the diagnosis of IP when obtained during stage 1 (vesicular). Characteristic histopathologic findings include eosinophilic spongiosis, intraepidermal vesicles containing eosinophils, and apoptotic keratinocytes in the epidermis. The pathologic changes seen in later stages are less specific, although they may show features that support the clinical diagnosis  (
         <a class="graphic graphic_table graphicRef109835" href="/z/d/graphic/109835.html" rel="external">
          table 1
         </a>
         ). A marked melanin incontinence with numerous melanophages in the dermis is noted in stage 3 (hyperpigmented) lesions.
        </p>
        <p class="headingAnchor" id="H2731565813">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2064139992">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         IP should be suspected in a female infant presenting with characteristic vesicular or hyperpigmented lesions occurring along the Blaschko lines  (
         <a class="graphic graphic_picture graphicRef111088 graphicRef58769" href="/z/d/graphic/111088.html" rel="external">
          picture 1A-B
         </a>
         ). At later stages, although the skin features may be less obvious clinically, the presence of teeth, hair, eye, or central nervous system (CNS) abnormalities should alert the clinician to the possibility of IP.
        </p>
        <p class="headingAnchor" id="H2311898494">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for IP were initially established in 1993 and were revised in 2014 [
         <a href="#rid2">
          2,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Major clinical criteria
         </strong>
         include the typical stages of the skin eruption distributed along the Blaschko lines, tooth anomalies, and demonstration of [
         <a href="#rid50">
          50
         </a>
         ] (see
         <a class="local">
          'Cutaneous findings'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical neonatal rash with erythema and vesicobullae (stage 1)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Verrucous papules or plaques along the Blaschko lines (stage 2)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical hyperpigmentation along the Blaschko lines fading in adolescence (stage 3)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Linear, atrophic, hairless lesions on limbs or scarring alopecia of the vertex (stage 4)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dental agenesis (hypodontia or oligodontia), shape anomalies (peg-shaped incisors, conical teeth, molar cusp pattern alteration), and delayed eruption
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Identification of the common deletion rearrangement in
         <em>
          IKBKG
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minor criteria
         </strong>
         include the extracutaneous manifestations of IP (see
         <a class="local">
          'Extracutaneous findings'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ocular anomalies (peripheral retinal neovascularization)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CNS anomalies
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alopecia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal hair
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal nails (punctuate depressions, onychogryphosis or ram's horn nails)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Palate anomalies
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nipple and breast anomalies
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maternal history of multiple male miscarriages
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical histopathologic findings in a skin biopsy  (
         <a class="graphic graphic_table graphicRef109835" href="/z/d/graphic/109835.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Pathology'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         At least two or more major criteria or one major and one or more minor criteria are required for the clinical diagnosis of IP.
        </p>
        <p class="headingAnchor" id="H3625481855">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In suspected cases with clinical and histopathologic findings suggesting IP, a targeted mutational analysis of deoxyribonucleic acid (DNA) extracted from peripheral blood should be performed to identify the common deletion of exons 4 to 10 in
         <em>
          IKBKG
         </em>
         , which is present in approximately 70 to 80 percent of cases [
         <a href="#rid4">
          4,6,51,52
         </a>
         ].
        </p>
        <p>
         Sequence analysis using Sanger sequencing may be needed in those cases (approximately 10 to 15 percent) in which the common deletion is not identified. Of note, next-generation sequencing cannot reliably be used for the molecular analysis of IP due to the presence of the highly homologous nonfunctional pseudogene
         <em>
          IKBKGP1
         </em>
         [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The detection of mosaic variants in males is especially difficult, as in males with IP, the mosaicism is limited to a small number of mutant cells, which may escape detection by the targeted analysis used in heterozygous females [
         <a href="#rid52">
          52
         </a>
         ]. In these cases, a biopsy of lesional skin (in children) and sperm samples (in adults) are appropriate tissue for sequence analysis.
         <em>
          IKBKG
         </em>
         variants can be in the blood only in samples taken from IP male newborns because blood leucocytes carrying the mutation could undergo selective apoptosis over time [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In male patients, karyotyping should be considered as well, due to the possibility of IP in the setting of chromosome aneuploidy 47,XXY (Klinefelter syndrome) [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2470084356">
         <span class="h2">
          Definitive diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definitive diagnosis of IP is established by demonstrating a pathogenic deletion of exons 4 to 10 or a pathogenic mutation in
         <em>
          IKBKG
         </em>
         . If genetic testing is not available, at least two or more major criteria or one major and one or more minor criteria are required to establish the diagnosis. (See
         <a class="local">
          'Genetic testing'
         </a>
         above and
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2458913218">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The skin conditions that should be included in the differential diagnosis of IP depend on the stage of the IP eruption (see
         <a class="local">
          'Cutaneous findings'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Herpes simplex virus infection
         </strong>
         – Neonates with any vesicular eruption must be suspected to have herpes simplex virus (HSV) infection. If the lesions are oriented along the Blaschko lines, HSV becomes less likely. Scrapings of vesicular contents for Tzanck smear, direct fluorescent antibody staining, or culture should be obtained for the diagnosis of possible HSV. (See
         <a class="medical medical_review" href="/z/d/html/6037.html" rel="external">
          "Neonatal herpes simplex virus infection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal varicella
         </strong>
         – In newborns born to mothers exposed to the varicella zoster virus within two weeks of delivery, the eruption starts as macules and rapidly progresses to papules and then to characteristic vesiculopustular lesions that heal in 7 to 10 days. The diagnosis can be confirmed by detection of the virus using polymerase chain reaction (PCR) from vesicular swabs or scrapings, scabs from crusted lesions, or tissue from biopsy samples. (See
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Staphylococcal infection
         </strong>
         – Staphylococcal skin infection should be considered in any infant presenting with pustular lesions. A Gram stain and culture of pustule content should be performed to rule out
         <em>
          Staphylococcus aureus
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">
          "Impetigo"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidermal nevus
         </strong>
         – The second or "warty" stage of IP can be confused with epidermal nevus. A skin biopsy may be useful in this instance to assist with diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/13728.html" rel="external">
          "Epidermal nevus and epidermal nevus syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          X-linked reticulate pigmentary disorder
         </strong>
         – X-linked reticulate pigmentary disorder is a rare condition inherited in a recessive X-linked fashion that can be seen in male and female individuals. Females will present with patchy hyperpigmentation. Male cases have the same pigmentation as in stage 3 IP in addition to systemic manifestations, including recurrent respiratory infections, failure to thrive, corneal dyskeratosis, gastrointestinal disorders, and hypohidrosis [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">
          "Congenital and inherited hyperpigmentation disorders", section on 'X-linked reticulate pigmentary disorder'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pigmentary mosaicism
         </strong>
         – Pigmentary mosaicism (hypomelanosis of Ito) is characterized by patchy or linear hyper- and hypomelanosis occurring along the Blaschko lines. In up to 30 percent of cases, pigmentary mosaicism is associated with eye, brain, or musculoskeletal abnormalities [
         <a href="#rid23">
          23
         </a>
         ]. Genetic testing for mutations of
         <em>
          IKBKG
         </em>
         (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma) can differentiate pigmentary mosaicism from IP. (See
         <a class="medical medical_review" href="/z/d/html/97404.html" rel="external">
          "Pigmentary mosaicism (hypomelanosis of Ito)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Naegeli-Franceschetti-Jadassohn syndrome or Naegeli syndrome
         </strong>
         – This dominantly inherited condition presents with reticulated hyperpigmentation and palmoplantar keratoderma in addition to hypohidrosis. This disorder has been associated with mutations in keratin 14 [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">
          "Congenital and inherited hyperpigmentation disorders", section on 'Naegeli-Franceschetti-Jadassohn syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H978961331">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of IP may involve multidisciplinary care depending upon the presence and severity of cutaneous and extracutaneous manifestations in the individual patient [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous lesions
         </strong>
         – The vesiculobullous lesions of the early stage of IP usually require only gentle wound care with mild detergents and emollients. Topical corticosteroids and topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         have been used successfully for severely inflamed areas [
         <a href="#rid58">
          58,59
         </a>
         ]. Patients with signs of secondary skin infection require treatment with local or systemic antimicrobial therapy. Stage 2 lesions, if significant and impacting movement of digits or extremities, may require emollients or topical retinoids. No treatment is generally needed for stage 3 or 4 skin lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ophthalmologic involvement
         </strong>
         – Ophthalmologic consultation and surveillance should be performed for all suspected and confirmed cases of IP [
         <a href="#rid60">
          60
         </a>
         ]. Devastating eye complications may present suddenly without proper monitoring [
         <a href="#rid4">
          4
         </a>
         ]. Eye examinations are recommended monthly until age four months, then every three months from age four months to one year, every six months from age one to three years, and annually after age three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Laser treatment of retinal neovascularization may be indicated to prevent retinal detachment [
         <a href="#rid61">
          61
         </a>
         ]. There are a few reports of the use of intravitreal
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">
          ranibizumab
         </a>
         (inhibitors of the vascular endothelial growth factors) as an adjunctive treatment to laser photocoagulation in children with IP [
         <a href="#rid62">
          62-64
         </a>
         ], though necrotizing enterocolitis has also been reported as an associated complication [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic involvement
         </strong>
         – For significant central nervous system involvement, ongoing neurologic follow-up will be needed. High-dose corticosteroids have been used for the treatment of severe seizure not responding to anticonvulsants [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dental anomalies
         </strong>
         – Dental consultation and management are indicated in all patients with IP at the time of teeth eruption or by age six months. Orthodontic care may be needed in mild cases. Severe cases with anodontia or hypodontia require coordinated care by dentists and oral surgeons from an early age. Use of flexible dentures is useful as early as two to three years to preserve jaw development [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2788148172">
         <span class="h1">
          GENETIC COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals affected with IP and families should be offered genetic consultation for consideration of mutation testing. Following molecular confirmation of the diagnosis in an affected child, parental testing should be offered whether or not the mother shows clinical signs suggestive of IP. Given the high frequency of de novo mutations in IP, estimated at approximately 65 percent, the mother may or may not have a pathogenic variant of
         <em>
          IKBKG
         </em>
         .
        </p>
        <p>
         Affected women have a 50 percent probability of transmitting the mutated X allele at conception. Since IP is lethal for the male embryo, the expected ratio among liveborn children is approximately 33 percent unaffected females, 33 percent affected females, and 33 percent unaffected males [
         <a href="#rid4">
          4
         </a>
         ]. Rare cases of father-to-daughter transmission of IP have been documented, due to germline mosaicism in fathers [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in the family has been identified. Preimplantation genetic testing can also be performed [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4036136903">
         <span class="h1">
          SUPPORT GROUPS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Support groups, such as the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2Fblog%2Fwelcome-incontinentia-pigmenti-families%2F&amp;token=hzDBxeIScCZhMxHyiBW%2FbLA5LWJybwSSAnM9UcChNlLpDwfUvQqQj9dhIA3WGHguVf8I6jnvN68%2FbWILNzHj6oU4po3MbA9olwfOiNi4kzk%3D&amp;TOPIC_ID=15513" target="_blank">
          Incontinentia Pigmenti International Foundation
         </a>
         , and organizations in other countries (eg, Italy [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fincontinentiapigmenti.it%2F&amp;token=0Ikl%2BItbwcu1ZTzu%2FIQNQXO5vvzHafU3Hnf7XH3DeJEP%2F2vUsrBDIqmuSNRejrZZ&amp;TOPIC_ID=15513" target="_blank">
          IPASSI
         </a>
         ]) provide immeasurable assistance to patients and their families/caregivers and should be fully engaged. Additional information can be found on the National Foundation for Ectodermal Dysplasias
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FyT8cU2O8GtHdX75aHgrsy4%3D&amp;TOPIC_ID=15513" target="_blank">
          website
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2743677133">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with IP who do not have clinically significant ophthalmologic or neurologic involvement have an excellent prognosis and a normal life expectancy. The skin, hair, or dental abnormalities are permanent and may be a cause of concern for some patients. For patients with brain or ocular involvement, the clinical course and prognosis is variable, based upon the type and extent of anomalies.
        </p>
        <p>
         Women with IP are at increased risk for pregnancy loss, due to low viability of affected male fetuses.
        </p>
        <p class="headingAnchor" id="H382833929">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Incontinentia pigmenti (IP) is an X-linked dominant genodermatosis that is usually lethal in males in utero. In females, it classically presents with a staged cutaneous eruption; variable developmental abnormalities involving the teeth, hair, and nail; and ocular and neurologic abnormalities. IP is caused by mutations in the
         <em>
          IKBKG
         </em>
         gene, also known as
         <em>
          NEMO
         </em>
         , encoding a regulatory protein involved in the activation of genes involved in cell survival, inflammation, and immunity. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Molecular pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Due to the X-linked dominant nature of IP, virtually all patients are female. In the classic presentation, the cutaneous lesions of IP are first noted during the neonatal period and evolve through four stages of variable duration: vesicular  (
         <a class="graphic graphic_picture graphicRef111088 graphicRef58769" href="/z/d/graphic/111088.html" rel="external">
          picture 1A-B
         </a>
         ), verrucous  (
         <a class="graphic graphic_picture graphicRef89806 graphicRef53297" href="/z/d/graphic/89806.html" rel="external">
          picture 2A-B
         </a>
         ), hyperpigmented  (
         <a class="graphic graphic_picture graphicRef111089 graphicRef63009 graphicRef89807" href="/z/d/graphic/111089.html" rel="external">
          picture 3A-C
         </a>
         ), and atrophic/hypopigmented. Lesions are typically distributed along the lines of Blaschko on the trunk and extremities. Common extracutaneous findings include dental, hair, and nail anomalies. Ocular and neurologic abnormalities occur in approximately one-third of the cases. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The clinical diagnosis of IP is based upon the presence in a female patient of the typical stages of the skin eruption distributed along the Blaschko lines. Minor diagnostic criteria include dental, hair, ocular, and neurologic abnormalities and typical histopathologic findings in a skin biopsy  (
         <a class="graphic graphic_table graphicRef109835" href="/z/d/graphic/109835.html" rel="external">
          table 1
         </a>
         ). The diagnosis is confirmed by molecular genetic testing demonstrating a loss-of-function mutation in the
         <em>
          IKBKG
         </em>
         gene. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of IP depends upon the significance of the cutaneous and extracutaneous involvement. The vesicular lesions of the early stage usually require only gentle wound care with mild detergents and emollients. Topical corticosteroids may be helpful for severely inflamed areas. Early pediatric ophthalmology evaluation and follow-up is recommended to prevent ocular complications. Dental and neurologic consultation are also indicated for all patients with IP. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Swinney CC, Han DP, Karth PA. Incontinentia Pigmenti: A Comprehensive Review and Update. Ophthalmic Surg Lasers Imaging Retina 2015; 46:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landy SJ, Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet 1993; 30:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayanan MJ, Rangasamy S, Narayanan V. Incontinentia pigmenti (Bloch-Sulzberger syndrome). Handb Clin Neurol 2015; 132:271.
          </a>
         </li>
         <li class="breakAll">
          Scheuerle AE, Ursini MV. Incontinentia pigmenti. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11:2371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Pescatore A, Steffann J, et al. Clinical utility gene card: for incontinentia pigmenti. Eur J Hum Genet 2019; 27:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenwrick S, Woffendin H, Jakins T, et al. Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am J Hum Genet 2001; 69:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aradhya S, Woffendin H, Jakins T, et al. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet 2001; 10:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smahi A, Courtois G, Vabres P, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minić S, Trpinac D, Obradović M. Incontinentia pigmenti diagnostic criteria update. Clin Genet 2014; 85:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conte MI, Pescatore A, Paciolla M, et al. Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease. Hum Mutat 2014; 35:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001; 27:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Paciolla M, Conte MI, et al. Incontinentia pigmenti: report on data from 2000 to 2013. Orphanet J Rare Dis 2014; 9:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pescatore A, Esposito E, Draber P, et al. NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. Cell Death Dis 2016; 7:e2346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupati A, Egbers RG, Helfrich YR. A case of incontinentia pigmenti reactivation after 12-month immunizations. JAAD Case Rep 2015; 1:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alikhan A, Lee AD, Swing D, et al. Vaccination as a probable cause of incontinentia pigmenti reactivation. Pediatr Dermatol 2010; 27:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AG, Goldberg MF, Gillard JH, et al. Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging. Arch Pediatr Adolesc Med 1995; 149:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller K, Courtois G, Ursini MV, Schwaninger M. New Insight Into the Pathogenesis of Cerebral Small-Vessel Diseases. Stroke 2017; 48:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridder DA, Wenzel J, Müller K, et al. Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. J Exp Med 2015; 212:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buinauskaite E, Buinauskiene J, Kucinskiene V, et al. Incontinentia pigmenti in a male infant with Klinefelter syndrome: a case report and review of the literature. Pediatr Dermatol 2010; 27:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Fimiani G, Tadini G, et al. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J Am Acad Dermatol 2007; 56:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alabdullatif Z, Coulombe J, Steffann J, et al. Postzygotic mosaicism and incontinentia pigmenti in male patients: molecular diagnosis yield. Br J Dermatol 2018; 178:e261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodemer C. Incontinentia pigmenti and hypomelanosis of Ito. Handb Clin Neurol 2013; 111:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheuerle AE. Incontinentia pigmenti in adults. Am J Med Genet A 2019; 179:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearlman J, Griego RD, Levy ML, Friedman J. An unusual presentation of incontinentia pigmenti in a 4-month-old girl. Pediatr Dermatol 1996; 13:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardelean D, Pope E. Incontinentia pigmenti in boys: a series and review of the literature. Pediatr Dermatol 2006; 23:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Leeuwen RL, Wintzen M, van Praag MC. Incontinentia pigmenti: an extensive second episode of a "first-stage" vesicobullous eruption. Pediatr Dermatol 2000; 17:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hand JL. What's new with common genetic skin disorders? Curr Opin Pediatr 2015; 27:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minić S, Trpinac D, Gabriel H, et al. Dental and oral anomalies in incontinentia pigmenti: a systematic review. Clin Oral Investig 2013; 17:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun SR, Rashid RM. Delayed onychodystrophy of incontinentia pigmenti: an evidence-based review of epidemiology, diagnosis and management. J Drugs Dermatol 2010; 9:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud BH, Zembowicz A, Fisher E. Controversies over subungual tumors in incontinentia pigmenti. Dermatol Surg 2014; 40:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pena ZG, Brewer JD. Multiple subungual squamous cell carcinomas in a patient with incontinentia pigmenti. Dermatol Surg 2014; 40:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballester Nortes I, Allegue Gallego F, López-Ávila A, et al. Painful subungual tumours. Clin Exp Dermatol 2013; 38:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadj-Rabia S, Rimella A, Smahi A, et al. Clinical and histologic features of incontinentia pigmenti in adults with nuclear factor-κB essential modulator gene mutations. J Am Acad Dermatol 2011; 64:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danford ID, Scruggs BA, Capone A Jr, et al. The Prevalence of Retinal Disease and Associated CNS Disease in Young Patients with Incontinentia Pigmenti. Ophthalmol Retina 2022; 6:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng J, Zhang Q, Long X, et al. Incontinentia pigmenti-associated ocular anomalies of paediatric incontinentia pigmenti patients in China. Acta Ophthalmol 2019; 97:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basilius J, Young MP, Michaelis TC, et al. Structural Abnormalities of the Inner Macula in Incontinentia Pigmenti. JAMA Ophthalmol 2015; 133:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu TYA, Han IC, Goldberg MF, et al. Multimodal Retinal Imaging in Incontinentia Pigmenti Including Optical Coherence Tomography Angiography: Findings From an Older Cohort With Mild Phenotype. JAMA Ophthalmol 2018; 136:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hübner S, Schwieger-Briel A, Technau-Hafsi K, et al. Phenotypic and genetic spectrum of incontinentia pigmenti - a large case series. J Dtsch Dermatol Ges 2022; 20:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minić S, Trpinac D, Obradović M. Systematic review of central nervous system anomalies in incontinentia pigmenti. Orphanet J Rare Dis 2013; 8:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soltirovska Salamon A, Lichtenbelt K, Cowan FM, et al. Clinical presentation and spectrum of neuroimaging findings in newborn infants with incontinentia pigmenti. Dev Med Child Neurol 2016; 58:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuwissen ME, Mancini GM. Neurological findings in incontinentia pigmenti; a review. Eur J Med Genet 2012; 55:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogasawara K, Honda Y, Maeda H, et al. Corticosteroid Therapy in Neonatal Incontinentia Pigmenti With Asymptomatic Cerebral Lesions. Pediatr Neurol 2019; 99:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauly E, Linderkamp O, Pöschl J. Incontinentia pigmenti in combination with decreased IgG subclass concentrations in a female newborn. Biol Neonate 2005; 88:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Pescatore A, Conte MI, et al. EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-κB pathway can cause immunodeficiency and/or inflammation. Int Rev Immunol 2015; 34:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alshenqiti A, Nashabat M, AlGhoraibi H, et al. Pulmonary hypertension and vasculopathy in incontinentia pigmenti: a case report. Ther Clin Risk Manag 2017; 13:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onnis G, Diociaiuti A, Zangari P, et al. Cardiopulmonary anomalies in incontinentia pigmenti patients. Int J Dermatol 2018; 57:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miteva L, Nikolova A. Incontinentia pigmenti: a case associated with cardiovascular anomalies. Pediatr Dermatol 2001; 18:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasuda K, Minami N, Yoshikawa Y, et al. Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti. Pediatr Int 2016; 58:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodemer C, Diociaiuti A, Hadj-Rabia S, et al. Multidisciplinary consensus recommendations from a European network for the diagnosis and practical management of patients with incontinentia pigmenti. J Eur Acad Dermatol Venereol 2020; 34:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang R, Lara-Corrales I, Kannu P, Pope E. Unraveling incontinentia pigmenti: A comparison of phenotype and genotype variants. J Am Acad Dermatol 2019; 81:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Pescatore A, Steffann J, et al. Clinical Utility Gene Card for: incontinentia pigmenti. Eur J Hum Genet 2013; 21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frans G, Meert W, Van der Werff Ten Bosch J, et al. Conventional and Single-Molecule Targeted Sequencing Method for Specific Variant Detection in IKBKG while Bypassing the IKBKGP1 Pseudogene. J Mol Diagn 2018; 20:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregersen PA, Sommerlund M, Ramsing M, et al. Diagnostic and molecular genetic challenges in male incontinentia pigmenti: a case report. Acta Derm Venereol 2013; 93:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull S, Arno G, Thomson P, et al. Somatic mosaicism of a novel IKBKG mutation in a male patient with incontinentia pigmenti. Am J Med Genet A 2015; 167:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pezzani L, Brena M, Callea M, et al. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A 2013; 161A:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugassy J, Itin P, Ishida-Yamamoto A, et al. Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. Am J Hum Genet 2006; 79:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaya TI, Tursen U, Ikizoglu G. Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti. Clin Exp Dermatol 2009; 34:e611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jessup CJ, Morgan SC, Cohen LM, Viders DE. Incontinentia pigmenti: treatment of IP with topical tacrolimus. J Drugs Dermatol 2009; 8:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CJ, Han IC, Tian J, et al. Extended Follow-up of Treated and Untreated Retinopathy in Incontinentia Pigmenti: Analysis of Peripheral Vascular Changes and Incidence of Retinal Detachment. JAMA Ophthalmol 2015; 133:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranchod TM, Trese MT. Regression of retinal neovascularization after laser photocoagulation in incontinentia pigmenti. Retina 2010; 30:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho M, Yip WWK, Chan VCK, Young AL. SUCCESSFUL TREATMENT OF REFRACTORY PROLIFERATIVE RETINOPATHY OF INCONTINENTIA PIGMENTI BY INTRAVITREAL RANIBIZUMAB AS ADJUNCT THERAPY IN A 4-YEAR-OLD CHILD. Retin Cases Brief Rep 2017; 11:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah PK, Bachu S, Narendran V, et al. Intravitreal bevacizumab for incontinentia pigmenti. J Pediatr Ophthalmol Strabismus 2013; 50 Online:e52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni Y, Huang X, Ruan L, et al. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. J AAPOS 2018; 22:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunzmann S, Ngyuen T, Stahl A, et al. Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report. BMC Pediatr 2019; 19:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomotaki S, Shibasaki J, Yunoki Y, et al. Effectiveness of Corticosteroid Therapy for Acute Neurological Symptoms in Incontinentia Pigmenti. Pediatr Neurol 2016; 56:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf DS, Golden WC, Hoover-Fong J, et al. High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti: a case report. J Child Neurol 2015; 30:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou-Yang LW, Li TY, Tsai AI. Early prosthodontic intervention on two three-year-old twin girls with ectodermal dysplasia. Eur J Paediatr Dent 2019; 20:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusco F, Conte MI, Diociaiuti A, et al. Unusual Father-to-Daughter Transmission of Incontinentia Pigmenti Due to Mosaicism in IP Males. Pediatrics 2017; 140.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15513 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26114846" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incontinentia Pigmenti: A Comprehensive Review and Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8423608" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Incontinentia pigmenti (Bloch-Sulzberger syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564087" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incontinentia pigmenti (Bloch-Sulzberger syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564087" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incontinentia pigmenti (Bloch-Sulzberger syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12351572" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31289372" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical utility gene card: for incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673821" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11590134" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10839543" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23802866" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incontinentia pigmenti diagnostic criteria update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24339369" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11242109" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24961275" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incontinentia pigmenti: report on data from 2000 to 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27560715" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27051777" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A case of incontinentia pigmenti reactivation after 12-month immunizations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20199413" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vaccination as a probable cause of incontinentia pigmenti reactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7735415" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28082670" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : New Insight Into the Pathogenesis of Cerebral Small-Vessel Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26347470" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Brain endothelial TAK1 and NEMO safeguard the neurovascular unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20807362" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Incontinentia pigmenti in a male infant with Klinefelter syndrome: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224368" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical diagnosis of incontinentia pigmenti in a cohort of male patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29077987" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Postzygotic mosaicism and incontinentia pigmenti in male patients: molecular diagnosis yield.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23622185" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Incontinentia pigmenti and hypomelanosis of Ito.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31119873" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incontinentia pigmenti in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8919526" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : An unusual presentation of incontinentia pigmenti in a 4-month-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17155991" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incontinentia pigmenti in boys: a series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720994" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Incontinentia pigmenti: an extensive second episode of a "first-stage" vesicobullous eruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26164153" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : What's new with common genetic skin disorders?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22453515" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dental and oral anomalies in incontinentia pigmenti: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20514792" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Delayed onychodystrophy of incontinentia pigmenti: an evidence-based review of epidemiology, diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25255281" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Controversies over subungual tumors in incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25255282" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Multiple subungual squamous cell carcinomas in a patient with incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23551236" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Painful subungual tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255870" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical and histologic features of incontinentia pigmenti in adults with nuclear factor-κB essential modulator gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35691580" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Prevalence of Retinal Disease and Associated CNS Disease in Young Patients with Incontinentia Pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073775" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Incontinentia pigmenti-associated ocular anomalies of paediatric incontinentia pigmenti patients in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26043102" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Structural Abnormalities of the Inner Macula in Incontinentia Pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29566114" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Multimodal Retinal Imaging in Incontinentia Pigmenti Including Optical Coherence Tomography Angiography: Findings From an Older Cohort With Mild Phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904373" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Phenotypic and genetic spectrum of incontinentia pigmenti - a large case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23406512" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Systematic review of central nervous system anomalies in incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27121774" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical presentation and spectrum of neuroimaging findings in newborn infants with incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22564885" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neurological findings in incontinentia pigmenti; a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31201074" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Corticosteroid Therapy in Neonatal Incontinentia Pigmenti With Asymptomatic Cerebral Lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16103646" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Incontinentia pigmenti in combination with decreased IgG subclass concentrations in a female newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26269396" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-κB pathway can cause immunodeficiency and/or inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28533687" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pulmonary hypertension and vasculopathy in incontinentia pigmenti: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29197078" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cardiopulmonary anomalies in incontinentia pigmenti patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207974" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Incontinentia pigmenti: a case associated with cardiovascular anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173419" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32678511" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Multidisciplinary consensus recommendations from a European network for the diagnosis and practical management of patients with incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30905793" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Unraveling incontinentia pigmenti: A comparison of phenotype and genotype variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23047738" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical Utility Gene Card for: incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29269280" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Conventional and Single-Molecule Targeted Sequencing Method for Specific Variant Detection in IKBKG while Bypassing the IKBKGP1 Pseudogene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23572116" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Diagnostic and molecular genetic challenges in male incontinentia pigmenti: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25944529" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Somatic mosaicism of a novel IKBKG mutation in a male patient with incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23613254" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16960809" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19489863" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19852125" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Incontinentia pigmenti: treatment of IP with topical tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25695859" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Extended Follow-up of Treated and Untreated Retinopathy in Incontinentia Pigmenti: Analysis of Peripheral Vascular Changes and Incidence of Retinal Detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20168266" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Regression of retinal neovascularization after laser photocoagulation in incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27472514" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : SUCCESSFUL TREATMENT OF REFRACTORY PROLIFERATIVE RETINOPATHY OF INCONTINENTIA PIGMENTI BY INTRAVITREAL RANIBIZUMAB AS ADJUNCT THERAPY IN A 4-YEAR-OLD CHILD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25313552" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Intravitreal bevacizumab for incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29630932" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31615465" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26777982" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effectiveness of Corticosteroid Therapy for Acute Neurological Symptoms in Incontinentia Pigmenti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682289" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31246091" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Early prosthodontic intervention on two three-year-old twin girls with ectodermal dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28794079" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Unusual Father-to-Daughter Transmission of Incontinentia Pigmenti Due to Mosaicism in IP Males.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
